Sanofi SA (NASDAQ:SNY) stock fell 2.53% (As on June 29, 11:18:49 AM UTC-4, Source: Google Finance) though the company in the second quarter of FY 22 has reported the business net profit of €2.17 billion for Q2 FY22, +25.4% (+16.6% at CER). Sales reached €10.11 billion, +15.7% Y/Y (+8.1% at constant exchange rates (CER)). Business operating income rose 21.5% to €2.75 billion. Best-selling eczema drug Dupixent, consumer healthcare, rare disease, and vaccines drove the growth. Specialty Care grew 21.6%, driven by Dupixent +43.4% to €1.96 billion and double-digit growth in Rare Disease. Vaccines were up 8.7% due to a strong rebound of Travel and Booster vaccines and continued growth in the Polio/Pertussis/Hib franchise. Consumer healthcare delivered the 5th consecutive quarter of growth (+9.1% to €1.26 billion) driven by Cough & Cold, Allergy, and Digestive Wellness. The company saw significant growth momentum from the Specialty Care business, mainly driven by Dupixent. While the company continues to increase the investment in R&D, the company delivered important pipeline milestones such as the approval of Dupixent in its fourth disease indication, Eosinophilic Esophagitis.

Sanofi expects 2022 business EPS to grow approximately 15% at CER. The positive currency impact on 2022 business EPS is estimated between +7.5% to +8.5%. Earlier, the company expected 2022 business EPS to grow low-double-digit at constant exchange rates, with a 4% – 5% positive currency impact. The company has reiterated its commitment to achieving the BOI margin target of 30% in 2022.

Meanwhile, Sanofi’s Global Health Unit launches a fund for healthcare solutions in underserved regions and Impact, a new brand dedicated for non-profit distribution of 30 Sanofi products to at-risk populations in 40 lower-income countries. Valyou program continues to improve access through lower out-of-pocket cost of insulins for uninsured patients in the U.S. Sanofi upgraded its scope 3 GHG emission reductions ambition to -30% by 2030, unveiling low energy intensity vaccines facility.

Additionally, Efanesoctocog alfa, the first factor VIII therapy to be granted FDA Breakthrough Therapy Designation for hemophilia A. Dupixent approved in the U.S as first treatment for adults and children aged 12 and older with eosinophilic esophagitis and as first biologic medicine for children aged 6 months to 5 years with moderate-to-severe atopic dermatitis. FDA accepted Dupixent for priority review in adults with prurigo nodularis. Nexviadyme and XenpozymeTM approved in EU. Next-generation COVID-19 booster demonstrated strong results against variants of concern, including Omicron.